“Part D Compensation — 550% gains, nine years of monthly checks”
This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for...
View ArticleThe Manchurian Candida
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and...
View ArticleAlzheimer’s Disease: 2019 Refresher and Updates
From where I sit, it seems to me that the entire landscape of Alzheimer’s disease (AD) has changed, and changed quite significantly. The litany of announcements from pharmaceutical companies big and...
View ArticleA Look at the Promise of Gene Editing
“CRISPR” is the word in the headline that signals that the piece is going to be about gene editing. Doc Gumshoe did not want to put that word – actually, it’s not really a word, but an acronym – in...
View ArticleWhat’s Bonner’s “FDA Fast Tracks $6.8 Billion Miracle Antibiotic” pitch about?
The latest teaser pitch from Jeff Brown has gotten a lot of attention from Gumshoe readers… so let’s dig in and get some answers (and yes, some readers already posted their findings in our discussions...
View ArticleWhat’s that “First and Best Drugs” Alzheimer’s Stock for 300% gains?
I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory...
View ArticleMichael Robinson’s “ONLY Solution” for COVID-19 (with June 30 Results Expected!)
This article was originally published on May 28, 2020, when we first saw these ads — they have recently been re-circulating as the June 30 date approaches and vaccine interest rises again. What follows...
View Article58,300% Sales Surge for “Super Vaccine” Company?
Newsletters have taken to hiring spokespeople for their promo videos, trying to give them that extra flash of veritas and professionalism and a nice “anchor voice”, and this time it’s actress and...
View ArticleAnother Look at the Current Migraine Scene
Thinking about COVID-19 almost gives me a migraine, or at least a heavy and achy sensation in my noggin – perhaps not an actual migraine, thankfully, but threatening and unpleasant all the same....
View ArticleCOVID 19: What Are Prospects for the Duration?
The term “the duration” immediately recalls the Second World War. Nobody had any idea when it would be over, and so discussions of a lot of World War II-related events and conditions prominently...
View ArticleWhat’s New on the CRISPR Front?
Aside from the tiny minority of people who can actually say what each of those initials stand for, we can divide the populace into two groups – those who specifically know that CRISPR is a tool used in...
View ArticleMay Miscellany – Some Covid-19, Some Otherwise
I’m happy to report that despite the huge quantity of COVID-related news items that flood my in-box (as well as all news media), the tsunami has not drowned other health and medicine-related releases....
View ArticleWhat’s Basenese’s “PGB” Stock? Thinkolator Answers Coming Your Way…
The intro to the latest ad from Lou Basenese has it all — tiny company, huge opportunity, mysterious name, and deadline, just about all you need to get readers fired up to pull out their credit card....
View ArticleCOVID-19: What Now?
Most of this Doc Gumshoe posting was ready to go a couple of days before Thanksgiving. But then, you know what happened: the new variant (now named Omicron) surfaced in South Africa. So I finished up...
View ArticleStansberry Venture’s “Major Announcement”— What are the Three Companies...
Dave Lashmet’s got a new ad out for his Stansberry Venture Technology ($2,500 “on sale” at the moment, list price $5,500, no refunds), and it’s pretty exciting — he talks up a big announcement that...
View ArticleAlex Green “Goes All-In” on Microcap — Says This Is His “#1 Stock for 2023”
Alexander Green is pitching some small companies, and talking up the idea of investing in microcap stocks during this market lull — he seems to think it’s an opportunity in small caps in general that...
View ArticleRelevant Updates – December 2022
I’m guessing that news about possible Alzheimer’s disease treatments is still relevant to most of us, so I’ll start with that. The results of the lecanemab trial are published. The reaction is mixed....
View ArticleOsteoporosis Update (Part Two)
Part One of this opus ended with a few paragraphs that approached the question of what we can do to prevent osteoporosis. Prevention is more important in the management of osteoporosis than in most...
View ArticleMarch 2023 Miscellany
My mission as Doc Gumshoe is almost the contrary of what the mainstream media do every day. They give prominence to disasters – a train wreck, an earthquake, an outbreak of a dire disease – which get...
View ArticleCancer 2023: What’s Happening in the Combat Zone?
Just over 50 years ago, President Richard M. Nixon signed into law the National Cancer Act of 1971, which established the National Cancer Institute. Cancer had become the second leading (after heart...
View Article